Clinical Research Papers:
Intraoperative use of dexmedetomidine promotes postoperative sleep and recovery following radical mastectomy under general anesthesia
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1544 views | HTML 2169 views | ?
Cunxian Shi1,*, Jin Jin1,*, Qiang Pan2, Shan Song1, Kezhong Li1, Jiahai Ma1, Tao Li1 and Zhi Li1
1 Department of Anesthesiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, P.R. China
2 Department of General Surgeon, Rushan People’s Hospital, Rushan, Yantai, Shandong, P.R. China
* These authors have contributed equally to this study
Jin Jin, email:
Jiahai Ma, email:
Keywords: dexmedetomidine, radical mastectomy, sleep disturbance, recovery, fatigue
Received: January 17, 2017 Accepted: April 28, 2017 Published: May 24, 2017
Postoperative sleep disturbance and fatigue following radical mastectomy were high risks for prolonged convalescence in patients with breast cancer. The present study was designed to observe the effect of intraoperative use of dexmedetomidine on postoperative sleep, fatigue and recovery following radical mastectomy under general anesthesia. Forty-seven patients were randomized into two groups that were maintained with propofol/remifentanil/Ringer’s solution (Control group), or propofol/remifentanil/Dexmedetomidine (DEX group) for surgery under general anesthesia. During the first night following surgery, patients receiving dexmedetomine spent more time sleeping when compared with those form the Control group. During the first week following operation, when compared with the Control group, patients from the DEX group had a higher score of global 40-item recovery questionnaire on day 3 following operation, and lower 9-question fatigue severity scores on day 3 and day 7 following operation. In conclusion, intraoperative use of dexmedetomidine is sufficient to improve postoperative sleep disorder, promote postoperative recovery. The adverse effect of dexmedetomidine on sleep disturbance might be contributed to its recovery-promoting effect.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.